RINVOQ®, the 15mg once-daily oral selective & reversible JAK inhibitor.1
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.1
One dose, one tablet,
once a day1
Once-daily oral treatment for your adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)1
Dosing recommendations1
- The recommended dose of RINVOQ is one 15mg tablet once a day, with or without food
The tablet should be swallowed whole, and should not be split, crushed, or chewed
RINVOQ may be taken at any time of the day
RINVOQ can be taken as monotherapy or in combination with methotrexate.1
Please consult the Summary of Product Characteristics for further details regarding monitoring requirements and contraindications prior to initiating RINVOQ.
Reference
- RINVOQ (upadacitinib) Summary of Product Characteristics, available at www.medicines.ie.
Date of preparation: June 2020 IE-RNQR-200012
RINVOQ HUMIRA – Legal Category: POM (S1A).
Further information is available on request from AbbVie Limited, 14 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, website: www.hpra.ie
